Vaxcyte, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for PCVX, updated each market day.
PCVX AI Sentiment
AI sees no strong directional signal for Vaxcyte, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Vaxcyte, Inc. Common Stock
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Sector
Exchange
Market Cap
$8,878,447,070
Cap Tier
Employees
507
Headquarters
SAN CARLOS, CA
Listed Since
June 12, 2020
Website
PCVX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PCVX Volatility
Vaxcyte, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
